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Non-transferrin-bound iron and its labile (redox active) plasmairon component are thought to be potentially toxic forms of ironoriginally identified in the serum of patients with iron overload.
We compared ten worldwide leading assays (6 for non-transferrin-
bound iron and 4 for labile plasma iron) as part of an international inter-
laboratory study. Serum samples from 60 patients with four different
iron-overload disorders in various treatment phases were coded and
sent in duplicate for analysis to five different laboratories worldwide.
Some laboratories provided multiple assays. Overall, highest assay lev-
els were observed for patients with untreated hereditary hemochro-
matosis and β-thalassemia intermedia, patients with transfusion-depen-
dent myelodysplastic syndromes and patients with transfusion-depen-
dent and chelated β-thalassemia major. Absolute levels differed consid-
erably between assays and were lower for labile plasma iron than for
non-transferrin-bound iron. Four assays also reported negative values.
Assays were reproducible with high between-sample and low within-
sample variation. Assays correlated and correlations were highest with-
in the group of non-transferrin-bound iron assays and within that of
labile plasma iron assays. Increased transferrin saturation, but not fer-
ritin, was a good indicator of the presence of forms of circulating non-
transferrin-bound iron. The possibility of using non-transferrin-bound
iron and labile plasma iron measures as clinical indicators of overt iron
overload and/or of treatment efficacy would largely depend on the rig-
orous validation and standardization of assays. 
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Introduction 
The predominant forms of iron present in living entities
are associated with proteins such as transferrin in the
major circulating fluid and heme and ferritin in cells.
However, the iron binding capacity of the iron transport
protein transferrin can be exceeded when a substantial
amount of iron enters the circulation due to excessive iron
absorption from the diet or release of iron from cell stores.
In these conditions non-transferrin-bound iron (NTBI; cir-
culating iron not bound to transferrin, ferritin or heme)
appears in the plasma.1-5 Plasma NTBI apparently com-
prises several subspecies, which may be classified by their
chemical composition, chemical reactivity or susceptibili-
ty to chelation.6-15 The chemical composition of NTBI is
heterogeneous and it is thought that there are several cir-
culating isoforms, that is Fe(III) bound to albumin and cit-
rate and potentially to acetate, malate and phosphate.6-8,14
Of these, citrate has the highest affinity for Fe(III), and
under physiological conditions two isoforms dominate,
i.e. monomeric and oligomeric Fe(III) complexes.8,16 The
fraction of plasma NTBI that is redox active and can be
chelated is designated labile plasma iron (LPI).12,13
Iron complexes assumed to represent NTBI have been
shown experimentally to be taken up by susceptible cell
types, including hepatocytes, cardiomyocytes and pancre-
atic islet cells, with consequent oxidant injury.5
Imbalances in iron homeostasis are responsible for a
variety of disorders. Excess iron accumulates in the circu-
lation and tissues of patients with hereditary hemochro-
matosis (HH), iron-loading anemias (β-thalassemia major
and intermedia), myelodysplastic syndromes (MDS) and
sickle-cell disease (SCD) after transfusion.2,3,5 To prevent
iron-induced tissue damage, impending iron toxicity must
be detected before complications develop and become
irreversible.
Currently, the most widely adopted method for the
detection of iron overload is the measurement of serum
ferritin, occasionally combined with transferrin saturation
(TSAT). However, it is well known that as an acute phase
reactant, serum ferritin levels are influenced by factors
such as inflammation and liver disease and are not, there-
fore, exclusively indicative of toxic parenchymal iron over-
load.17 Moreover, with the introduction of T2*-weighted
magnetic resonance imaging for the assessment of tissue
iron overload,18 it became clear that organs such as the
heart and endocrine glands load iron differently compared
to the liver and non-commensurately with serum ferritin.
Studies of plasma NTBI in patients with thalassemia major
suggest that NTBI may be an important early indicator of
extra-hepatic iron toxicity.19 Studies in patients with vari-
ous iron-loading disorders have shown reductions in NTBI
and LPI upon phlebotomy and chelation therapy and that
these reductions are associated with an improved progno-
sis.2,3,20-23 The results of NTBI and LPI assays are, therefore,
promising as therapeutic targets and for the evaluation of
iron overload and the efficacy of and compliance with
iron-lowering therapies.5,13,24
Due to the complexity and potential clinical importance
of NTBI, several assays have been developed for its detec-
tion.6,10-12,15,25-29 In our previous round robin 1 we found that
NTBI values of patients with HFE-related hemochromato-
sis differed considerably depending on which of various
assays was used.30 We concluded that NTBI assays were
insufficiently standardized and the most pertinent assay
for clinical applications was uncertain. Since that round
robin 1 for NTBI, novel assays have been published and
made available for use.12,15,29 Therefore, and as a stepping
stone in the path to defining the clinical utility of these
assays, the aims of our study were to update round robin 1
and to increase our understanding of the various NTBI and
LPI levels measured by the current leading analytical assays
in four different groups of iron-overloaded patients (those
with HH, thalassemia, MDS, and SCD) undergoing various
treatments (phlebotomy, iron chelation, red blood cell
transfusion). More specifically, in these populations of
patients, we aimed to: (i) establish correlations between
assays, (ii) establish levels of reproducibility of each of the
assays, (iii) assess levels of the NTBI fraction consisting of
iron citrate, and (iv) correlate assays with other established
parameters of iron overload (e.g. TSAT and serum ferritin).
Methods
Study design and participants
We compared ten different assays (5 NTBI, 1 NTBI isoform-spe-
cific and 4 LPI) performed in five different laboratories worldwide.
Serum samples (n=60) were collected from patients with four iron
overload disorders in different treatment phases (transfusion-
dependent; receiving iron chelation) making a total of ten different
patient and treatment groups. Samples were collected with
approval from local Institutional Review Boards and in conformity
with the code for proper secondary use of human tissues. More
detailed information on the collection of samples and laboratory
analyses are given in the Online Supplementary Information.
Non-transferrin-bound iron and labile plasma 
iron assays
The NTBI/LPI assays were divided into three different groups: (i)
five NTBI assays (N1-N5); (ii) one NTBI isoform-specific assay (N6);
and (iii) four LPI assays (L1-L4) (Online Supplementary Table S1). The
test principles of the NTBI assays can be divided into two sub-
groups. The first subgroup (N2-4) consists of a chelation-ultrafiltra-
tion-detection approach based on the prior mobilization of serum
NTBI by weak iron-mobilizing chelators such as nitrilotriacetate at
80 mM. The chelated NTBI is separated from transferrin-bound
iron by ultrafiltration and detected by colorimetry or high perform-
ance liquid chromatography.26-28 The second subgroup of NTBI
assays (N1 and N5) comprises the measurement of directly chelat-
able iron. In these assays NTBI is mobilized and detected in the
same reaction mixture by iron-binding probes such as fluorescent-
ly-labeled desferrioxamine and the hexadentate pyridinone chela-
tor (CP851) attached to a fluorescent probe.6,10,15 In the latter assay
the CP851 was bound to beads and the fluorescent signal from the
bead-bound chelator was differentiated from the non-specific plas-
ma signals by flow cytometry.6,15 None of the NTBI assays used a
cobalt compound to block unsaturated transferrin. The NTBI iso-
form-specific method N6 measures the sum of the oligomeric and
monomeric iron (III)-citrate complexes of NTBI. This methodology
consists of gel filtration chromatography by high performance liq-
uid chromatography to separate the individual components of
NTBI by mass, followed by quantification of iron by inductively
coupled-plasma mass spectrometry (LC-ICP-MS).6
The LPI assays (L1-4) measure the redox active component of
NTBI, a potentially toxic species. Assay L1 used bleomycin, which
forms a complex with DNA and redox active ferrous iron. When
ascorbate is added, reactive oxygen species are generated which
degrade the deoxyribose moieties of the DNA in a site-specific
reaction. These degradation products bind to thiobarbituric acid to
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give a pink chromogen for quantification.25 The assays L2, L3 and
L4 used a reducing agent (ascorbate) and an oxidizing agent
(atmospheric O2) to generate reactive oxygen species from
endogenous oxidants and labile catalytic iron. Reactive oxygen
species were detected by an oxidation-sensitive probe (dihy-
drorhodamine). Comparison of the generated fluorescence in the
presence and absence of an iron chelator (deferiprone or deferriox-
amine) makes the assay specific for iron, which can then be meas-
ured from a standard curve generated from known iron concentra-
tions.12,29 For the extraction of iron from NTBI, assay L4 used 0.1
mM nitrilotriacetate to capture the mobilizer-dependent form of
LPI (enhanced LPI).11, 29
The statistical analysis is described in detail in the Online
Supplementary Information.
Results
Patients’ characteristics 
The characteristics of the patients, divided by disease
and treatment group, are shown in Table 1. Serum ferritin
levels were highest in patients with transfusion-dependent
thalassemia major, MDS or SCD, in thalassemia major
patients receiving iron chelation therapy and in HH
patients at presentation. The ferritin levels in HH patients
decreased after phlebotomy. TSAT levels were similar for
the two different TSAT methodologies used and were
highest in thalassemia major patients who were transfu-
sion-dependent or receiving iron chelation (median
100%). The median TSAT was also very high (>94%) in
patients with HH or thalassemia intermedia at presenta-
tion, transfusion-dependent MDS and less increased
(>51%) in patients with thalassemia major at presenta-
tion, in the depletion phase of phlebotomies in HH
patients, in MDS subtypes refractory anemia with ringed
sideroblasts/refractory cytopenia with multilineage dys-
plasia with ringed sideroblasts and in transfusion-depen-
dent SCD. The median TSAT was within the reference
range (<45%) for most SCD patients at presentation and
HH patients in the maintenance phase. 
Assay levels and limits of detection  
Absolute NTBI and LPI levels differed considerably
between assays (Table 2). Overall, the NTBI assays (N1-N4,
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Table 1. Patients’ characteristics by disease and treatment groups. Median (range) are given for five to seven measurements in each disease and
treatment group. 
Age Hb MCV CRP LDHe Iron Ferritin TSAT immuno TSAT gel
Diseasec N years mmol/La fL mg/L U/L mmol/L mg/L % % 
Hemochromatosis
1. Naïve 6 58 (42-66) 9.5 (8.4-10.0) 91 (82-96) 0 (0-0) 157 37 1389 97 100
(128-238) (33-44) (948-2049) (76-100) (80-100)
2. Depletion 6 59 (42-66) 8.5 (7.9-9.0) 93 (85-104) 0 (0-0) 121 31 631 66 58
(105-140) (18-39) (570-786) (35-89) (31-95)
3. Maintenance 6 59 (43-67) 9.2 (8.3-9.6) 90 (82-97) 0 (0-0) 126 23 58 44 43
(112-144) (10-36) (30-166) (21-95) (24-100)
β-Thalassemia
4. Major Naïve 6 1 (0.5-2) 5.7 (4.6-6.6) 81 (73-84) 0 (0-5) 252 24 912 52 52
(233-478) (17-29) (639-2060) (43-94) (46-100)
5. Major TD & CHb 6 31 (28-35) 6.0 (5.4-6.3) 84 (82-86) 0 (0-0) 127 38 2507 100 100
(91-141) (17-46) (623-5451) (45-103) (47-100)
6. Intermedia Naïve 7 39 (22-60) 5.5 (4.7-6.3) 85 (64-94) 0 (0-6) 228 35 487 95 100
(150-550) (16-42) (306-940) (42-103) (48-100)
MDS
7. RARS/RCMD-RS 6 69 (26-77) 6.7 (5.4-7.4) 97 (79-99) 0 (0-0) 190 35 474 71 52
(105-292) (17-39) (289-826) (31-90) (31-88)
8. TD 5 71 (68-85) 4.6 (4.0-5.6) 92 (87-97) 20 (0-275) 181 30 2633 94 100
(161-290) (19-45) (1379-11834) (93-106) (92-100)
Sickle cell disease
9. Naïve 6 34 (18-57) 5.2 (4.1-7.1) 87 (76-114) 0 (0-6) 437 19 164 37 37
(290-864) (11-27) (79-996) (18-58) (28-48)
10. TDd 6 23 (19-41) 5.9 (4.2-6.5) 85 (81-90) 3 (0-30) 448 25 2091 62 51
(231-649) (7-38) (1451-5353) (19-95) (17-100)
Reference range
Male - - 8.5-11.0 80-100 <10 <250 14-35 25-250 <45 <45
Female - - 7.5-10.0 80-100 <10 <250 10-25 20-250 <45 <45
Naïve: before start of any therapy; depletion: during the depletion phase of phlebotomy treatment; maintenance: during maintenance phase of phlebotomy. TD: transfusion-depen-
dent; CH: receiving iron chelation therapy;  RARS: refractory anemia with ringed sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia;  Hb: hemoglobin; MCV: mean
corpuscular volume; CRP: C-reactive protein; LDH: lactate dehydrogenase; iron: serum iron; ferritin: serum ferritin; TSAT immuno, transferrin saturation, transferrin measured immuno-
chemically and iron with a colorimetric method, both on an automated analyzer; TSAT gel: transferrin saturation measured with gel electrophoresis; NA: not available; Hb and MCV
in thalassemia patients were from the first sampling due to pooling afterwards. aHb (g/dL) = mmol/L x 1.6206; bchelation consisted of deferiprone (Ferriprox, DFP, n=2) and
deferasirox (Exjade, DFX, n=4); cthe disease groups have been given numbers as identities; d: including five patients on iron chelation therapy that consisted of DFP (n=3) and DFX
(=2);  e: the hemolytic index (reflecting in vivo and ex vivo hemolysis) levels were within the reference range (<20 mg/dL) for all samples (data not shown).  Patients with SCD
were of African descent (African-Dutch) and the patients with β-thalassemia were all Italian-Caucasian (Italians). All other patients were Dutch-Caucasian.
N6) measured ~2-30 times higher concentrations compared
to the LPI assays (L1-L4), in agreement with the concept
that NTBI assays measure total circulating NTBI, whereas
LPI assays specifically measure the redox active fraction.
Nonetheless, major differences in absolute values were
found within the group of NTBI and LPI assays. For exam-
ple, both N1 and N5 measure directly chelatable iron but
levels were much higher for N1 than for N5. In fact, N5 lev-
els were greater than the cut-off of zero in only 8% of the
samples (n=5). This assay was, therefore, excluded from
further analysis.   
As expected, levels of assay L4, which measures the
forms of LPI that are detectable in the presence of nitrilotri-
acetate (designated “enhanced LPI”), were higher than those
obtained by assay L3 that uses a methodology that is iden-
tical to L4 except that nitrilotriacetate is not added. 
Assays differed widely in the use of predefined detec-
tion limits (Online Supplementary Table S1). Four out of ten
methods studied reported negative values: i.e. N1, N2, L1
and L2 in 20%, 60%, 53% and 25% of the samples,
respectively. For assays N5, L3 and L4, 92%, 70%, and
28% of the samples, respectively, were measured as ≤0
but were reported as 0 (zero) NTBI or LPI. For two of these
assays, L3 and L4, an upper limit of detection (LOD) of 2.2
mmol/L was also employed since the assay is non-linear
above this concentration. Three assays (N3, N4, and N6)
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Table 2. Mean (SD, in µmol/L) of the NTBI and LPI values by assay, disease and treatment. 
N NTBI assays LPI assays 
Assay ID N1 N2e N3a N4b N6 L1 L2 L3c,d L4c,d
Assay subgroup DCI NTBI NTBI NTBI Isoform LPI LPI LPI eLPI
Disease/Total 60 1.60 (0.37) -0.73 (0.20) 1.32 (0.14) 2.19 (0.64) 1.10 (0.15) 0.09 (0.07) 0.24 (0.17) 0.14 (0.04) 0.46 (0.11)
Hemochromatosis
1. Naïve 6 2.61 (0.43) 0.42 (0.19) 2.08 (0.16) 3.25 (0.73) 1.58 (0.22) 0.21 (0.11) 0.39 (0.13) 0.10 (0.06) 1.34 (0.31)
2. Phlebotomy 6 0.36 (0.30) -1.32 (0.20) 0.66 (0.13) 1.15 (0.20) 1.36 (0.15) -0.04 (0.05) -0.09 (0.14) 0.00 (0.00) 0.03 (0.04)
3. Maintenance 6 0.25 (0.26) -1.52 (0.15) 0.57 (0.02) 0.91 (0.35) 1.19 (0.19) -0.07 (0.03) 0.02 (0.15) 0.00 (0.00) 0.05 (0.03)
β-Thalassemia
4. Major Naïve 6 0.61 (0.25) -1.19 (0.17) 0.76 (0.05) 1.68 (1.07) 1.08 (0.36) -0.01 (0.04) 0.08 (0.09) 0.01 (0.01) 0.17 (0.05)
5. Major TD & CH 6 5.79 (0.65) 0.38 (0.27) 2.46 (0.12) 4.00 (0.67) 0.87 (0.11) 0.43 (0.12) 0.68 (0.24) 0.54 (0.15) 1.43 (0.17)
6. Intermedia Naïve 7 3.32 (0.44) 0.04 (0.17) 2.46 (0.17) 3.74 (2.25) 1.51 (0.06) 0.28 (0.10) 0.64 (0.25) 0.52 (0.06) 0.83 (0.14)
MDS
7. RARS/RCMD-RS 6 0.14 (0.16) -1.38 (0.25) 0.61 (0.03) 1.37 (0.20) 1.11 (0.05) -0.05 (0.02) 0.04 (0.17) 0.00 (0.00) 0.02 (0.03)
8. TD 5 2.97 (0.81) 0.53 (0.15) 2.33 (0.43) 3.65 (0.31) 0.60 (0.04) 0.22 (0.10) 0.62 (0.23) 0.20 (0.11) 0.66 (0.29)
Sickle cell disease
9. Naïve 6 -0.10 (0.24) -2.01 (0.15) 0.44 (0.22) 0.49 (0.12) 0.94 (0.06) -0.06 (0.04) -0.01 (0.12) 0.00 (0.00) 0.01 (0.01)
10. TD & CH 6 -0.05 (0.19) -1.12 (0.32) 0.86 (0.14) 1.69 (0.20) 0.57 (0.21) 0.00 (0.04) -0.01 (0.15) 0.00 (0.00) 0.06 (0.06)
Assay ID: random numbering within assay group. Each mean was calculated as the outcome of the means of a total of four NTBI or LPI measurements (2 days, 2 measurements
with exception of 2 methods, 1 which performed assays over 4 days, 1 measurement and 1 which performed 1 day, 2 measurements), according to the number of patients in each
disease category (n=5-7). NTBI assays: measurement of total NTBI using chelators such as nitrilotriacetate or desferrioxamine as scavenging agent; LPI assays: measurement of
redox active fraction of NTBI using reducing agents such as ascorbate or bleomycin to induce redox cycling and generate reactive oxygen species; NTBI isoform-specific measure-
ment of the iron-citrate fraction in the serum samples; DCI: direct chelatable iron; eLPI: enhanced LPI. Method N5 (DCI) has been omitted from this table since NTBI was only present
in 8% of the samples (n=5: 3 thalassemia major, transfusion-dependent or receiving iron chelation therapy, 1 untreated thalassemia intermedia, 1 transfusion-dependent MDS); a,b:
for statistical calculations, results below the LLOD of 0.60 and 0.87 were included as 0.30 and 0.40, respectively; c: results were recommended to be interpreted as follows: X <0.1
=negative, 0.1 ≥ X <0.2 = undetermined, X ≥0.2 = positive; d: for statistical calculations, results above the upper LOD of 2.2 were included as 2.4 mmol/L;  e: range of levels assessed
in healthy individuals (23-61 years, 50% men; TSAT 16-56%): -2.29 to 0.35 µmol/L.
Table 3.  The between-sample and within-sample variation of the assay concentrations by method. 
SD (µmol/L) Variance (%)
Method Total Between- Within-sample Residual Between- Within-sample Residual
sample sample
Within-day Between-day Within-day Between-day
N1 3.20 3.15 0.00 0.15 0.51 97.2 0.0 0.2 2.6
N2 1.23 1.19 0.00 0.18 0.21 94.8 0.0 2.2 3.0
N3 1.18 1.15 NA 0.06 0.25 95.3 NA 0.2 4.5
N4 2.07 1.70 0.07 0.00 1.19 67.1 0.1 0.0 32.8
N6 1.08 1.05 0.00 0.00 0.26 94.3 0.0 0.0 5.8
L1 0.26 0.24 0.00 0.03 0.08 87.7 0.0 1.3 11.0
L2 0.51 0.47 0.00 0.00 0.21 83.5 0.0 0.0 16.5
L3 0.40 0.38 0.00 0.00 0.10 94.0 0.0 0.0 6.0
L4 0.69 0.67 0.00 0.00 0.18 93.5 0.0 0.0 6.5
SD: standard deviation, absolute error; between-sample SD: segment due to variation between samples; within-sample within-day: segment due to variation in repeated measure-
ments on the same day; within-sample between-day: segment due to variation in repeated measurements on two different days. NA: not available, measurements were on four
different days instead of twice on two different days. For N6 only a duplicate measurement on day 2 is available because of iron contamination issues on day 1.
measured positive values only. Two of them (N3 and N4)
applied a lower LOD of 0.60 mmol/L and 0.87 mmol/L with
reported results below the lower LOD in 42% and 32% of
the samples, respectively.
Reproducibility 
Assays gave a large contribution of the between-sample
variance to the total variance indicating that the assays are
able to identify different NTBI/LPI concentrations in the var-
ious groups of patients (Table 3). The relatively low between-
sample variance of assay N4 could be attributed to the rela-
tively high residual variance (33%) due to some outliers.
For all assays, the contribution of the within-sample
variance (within day and between-day) to the total vari-
ance was relatively low (0-2.2%), indicating good repro-
ducibility.
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Figure 1. Bland-Altman
plots showing differ-
ences in mean NTBI or
LPI levels (mmol/L)
between two methods
versus the average of the
mean values of these
two methods. Solid lines
represent the mean dif-
ference between the two
methods. Thick dashed
lines represent the 95%
confidence interval. Thin
dashed lines at 0 refer to
no difference between
methods. Dots represent
the means of duplicates
on day 2. Note that
absolute values on both
axes differ between
plots. 
Table 4. Spearman correlation coefficients between the assays, using the mean of the duplicate measurements on day 2.
N1 N2 N3 N4 N6 L1 L2 L3
N2 0.60 -
N3 0.57 0.88 -
N4 0.57 0.85 0.86 - -
N6 -0.06 -0.06 -0.06 -0.11
L1 0.50 0.89 0.85 0.83 0.05 -
L2 0.59 0.54 0.48 0.44 0.05 0.54 -
L3 0.75 0.73 0.69 0.62 0.03 0.72 0.74 -
L4 0.62 0.71 0.63 0.58 0.13 0.67 0.57 0.77
Bland-Altman plots of the bold numbers are presented in Figure 1. Correlation plots of all cells are provided in Online Supplementary Figure S1. 
Comparison between assays 
Overall, assays correlated well and correlations were
highest within the same group of NTBI or LPI assays
(Table 4, Online Supplementary Figure S1). The NTBI and
LPI assays with the highest mutual Spearman correlation
were N2 and N3 (rs=0.88), N3 and N4 (rs=0.86), N2 and N4
(rs=0.85), L3 and L4 (rs=0.77), and L2 and L3 (rs=0.74).
Spearman correlations of N6 with the other assays were
all <0.10. 
Remarkably, the Spearman correlation of LPI assay L1,
using bleomycin, with NTBI assays was higher than with
the LPI assays. In contrast, NTBI assay N1 showed a better
Spearman correlation with LPI assays than with NTBI
assays (Table 4). 
Figure 1 shows the Bland–Altman plots of a selection of
nine graphs with the highest mutual correlation or a spe-
cific correlation of interest. Two patterns can be observed
in the plots: (i) if the scales of one variable are small com-
pared to the other one, there is a straight line pattern (e.g.
in the N2-L1 plot); and (ii) if cut-off values are used in one
variable and not in the other variable, a straight line occurs
in combination with a scattered pattern (e.g. the N2-N3
plot). 
Discrimination of disorder and treatment groups 
by the assays  
Table 2 shows the results obtained by the ten assays in
the ten different disease and treatment groups. Using a lin-
ear mixed model, we found that all methods were suitable
to discriminate, at least on a group level, between some
different types of iron-overload disease (P<0.05), except
for the NTBI isoform-specific assay N6 (P=0.268) (Online
Supplementary Table S2).  Overall, assays were best in dis-
criminating LPI and NTBI from patients with highest
TSAT levels (thalassemia major patients who are transfu-
sion-dependent or receiving iron chelation therapy, tha-
lassemia intermedia patients, transfusion-dependent MDS
patients and untreated HH patients) from those of the dis-
eases with lower TSAT (untreated and transfusion-depen-
dent SCD, HH maintenance; Table 2 and Online
Supplementary Table S2). 
Comparison of assay results with transferrin saturation
and ferritin levels
The assays show either a hyperbolic relationship or a
threshold effect with TSAT, regardless of the underlying eti-
ological condition, NTBI concentrations increase sharply
when TSAT levels exceed 70%, NTBI is sporadically
observed in samples with TSAT lower than 70% and LPI is
found essentially when TSAT exceeds 90% (Figure 2). More
specifically, at TSAT >90%, the presence of LPI and NTBI
may be taken for granted for N1, N2, N3, N4, N6, L1 and L4
since for these assays the proportion of samples in which
NTBI or LPI is found is 95.7% or 100%.  At TSAT >70%,
these proportions are somewhat lower, but for N3 and N6
already 100%  (Online Supplementary Table S3). 
There is no relationship between serum ferritin and
either LPI or NTBI measured in any of the assays (data not
shown). 
Discussion
We compared the performance of ten different NTBI
and LPI assays in patients with four different iron-over-
load diseases in various treatment phases. Nine out of
the ten assays reported an assay value above zero in
≥30% of the samples. These nine methods exhibited a
high between-sample variation and low within-sample
variation indicating their suitability to identify different
serum NTBI and LPI concentrations in patients with iron-
overload. Overall, results correlated both within the
group of five NTBI assays and in the group of the four
LPI assays, but between group correlations were also
present. Nonetheless, absolute assay levels differed con-
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Figure 2.  Relationship between the assay concentrations and transferrin satu-
ration (TSAT). Assay results are given for day 2 as duplicate measurements (cir-
cles and triangles). 
siderably between assays, with lowest levels for LPI
methods. Overall, assay levels correlated with TSAT but
not with ferritin concentrations and iron-overload dis-
eases with the highest TSAT also had the highest levels
of NTBI and LPI. 
Some of the differences in absolute values between the
assays can be attributed to differences in the assay princi-
ples that result in the measurement of different NTBI
entities, e.g. NTBI directly chelatable iron, NTBI-iron cit-
rate, LPI and enhanced LPI.3,11 In addition, minor varia-
tions in analytical procedures between methods aimed at
the measurement of the same entities (N2-N4 or N1 and
N5 or L2 and L3) may also have contributed to between-
assay variation in absolute values. For instance, it has
recently been shown that, for nitrilotriacetate-based
assays that use filtration, centrifugation at extremely high
speed can lead to overestimation of the NTBI concentra-
tion due to passage of transferrin-bound iron through the
filter membrane. Conversely, when centrifuging at lower
speed, iron-nitrilotriacetate complexes do not pass the
membrane, leading to underestimation.31 The LPI assays
also differ with regards to reagents and buffers. The pres-
ence of residual chelator or chelates could contribute to
higher values in some assays, such as the bleomycin-
based LPI (L1) assay and the nitrilotriacetate-filtration
assays (N2-N4), but not in others.11
Furthermore, iron contamination may also be a source
of variation in absolute assay concentrations.32 It could
contribute to the reported negative values by mimicking
free circulating iron. Rather than registering as an increase
in NTBI, this contaminant free iron can shuttle from the
iron chelator nitrilotriacetate to vacant binding sites on
transferrin.27,31,33 Thus samples containing unsaturated
transferrin may have lower NTBI values compared to
standards in which no transferrin is present. In principle,
this can result in underestimation of NTBI and negative
values. This iron shuttling can be prevented by saturating
transferrin with cobalt(III) prior to addition of the nitrilo-
triacetate.34 Still, others have reported that the addition of
cobalt (III) may result in substantial iron-contamination
that could account for a rise in NTBI even in normal indi-
viduals.32 Finally, with regards to the iron chelator nitrilo-
triacetate, applied in three NTBI assays, the use of 80 mM
was shown by some authors to remove 1-8% of the iron
bound to transferrin in the case of elevated TSAT, thus
leading to overestimation of NTBI measurements.27,31 By
contrast, at physiological concentrations of serum iron in
control subjects others reported no mobilization of iron
from transferrin under these conditions.28
NTBI is thought to consist of Fe(III) bound to several
ligands. Since iron bound to citrate is likely to be the most
prevalent isoform of NTBI in most conditions, a LC-ICP-
MS assay for the sum of these Fe(III)-citrate complexes of
NTBI was developed and included as N6 in the current
round robin.6 The assay was reproducible and discrimi-
nated between samples, but assay levels did not correlate
with other assays and could not discriminate between
any of the disorders. Clearly, this method may need opti-
mization, but if successful, we anticipate that quantifica-
tion of NTBI subspecies could provide the basis for fur-
ther studies on their toxicity. Different methods may not
be equivalent at measuring these subspecies. It has been
postulated that the abundance of each subspecies varies
with the type and degree of iron-overload disease.7,11
Although this possibility is still under investigation, it
implies that specific assays might be required for different
chemical species of NTBI.6,7,11,13
Overall the assays correlated well. Mutual correlations
between the assays were found to be highest for methods
based on a similar principle (i.e. in the group of NTBI
assays and the group of LPI assays). We observed two
unexpected correlations: first, despite the chelator-based
principle of N1, the correlation of N1 with LPI assays
exceeded its correlation with other NTBI assays. A possi-
ble explanation could be the kinetics of access of CP851
to redox active NTBI.6,12,15,27 Secondly, even though assay
L1 is based on binding of the antibiotic bleomycin to
redox active iron and DNA, its results correlated slightly
better with most NTBI assays than with LPI assays.
Bleomycin-detectable NTBI might represent a larger
redox active fraction of NTBI than LPI, in equilibrium
with a larger, still uncharacterized pool of NTBI. 
Differences in the range of reported values, as well as in
absolute values, have highlighted the urgent need for
thorough method-validation protocols, standardization
and consensus on how best to report assays before their
introduction in clinical use. Four out of ten assays report
negative values and as such provide information on the
residual iron-binding capacity of transferrin. Other assays
report 0 (zero) for results ≤0, or below the lower LOD for
results that do not significantly differ from 0. It remains to
be determined which reporting strategy is clinically more
useful.
Importantly, both LPI and NTBI assays showed a rela-
tionship with TSAT, irrespective of the type of iron-over-
load disease. NTBI and LPI were essentially found above
certain thresholds of TSAT, lower for NTBI (~70%) than
for LPI (~90%). A comparable pattern was previously
reported for LPI assays that were similar to assays L1-L3
for patients with various conditions.2,3,35,36 Altogether, our
findings corroborate previous reports in HH and tha-
lassemia patients that TSAT levels of around 70% can be
considered as a threshold for the presence of potentially
toxic iron species.2,3 Nonetheless, because a single meas-
urement only reflects the labile iron species present dur-
ing the previous 24-48 hours, repeated measurements are
imperative to assess a potential risk of impending NTBI
toxicity.18
The majority of the assays in the current round robin
have given useful insights into the efficacy of iron chela-
tion in transfusional siderotic patients and of phlebotomy
in patients with HH.2,3,9,13,19-22,37-40 Despite this finding, in the
absence of studies that assess the independent relation of
assay levels to clinical outcome in these various categories
of patients, the clinically most relevant assay formats and
their decision limits remain unknown. 
In conclusion, several novel methods have been devel-
oped since the previous round robin for NTBI, including
LPI and directly chelatable iron assays and first attempts
to specifically determine the NTBI iron-citrate isoforms.
While NTBI and LPI values of various assays were well
correlated and were reproducible, absolute values differed
considerably. The assay(s) that best represent the clinical-
ly relevant species and are most relevant for diagnostic
and therapeutic purposes could not be determined from
this study. Before NTBI and LPI assays can be introduced
into clinical practice, rigorous validation and standardiza-
tion of assays, consensus on how to report the results,
L. de Swart et al.
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and clinical outcome studies to determine clinically rele-
vant assay formats and their toxic thresholds are needed. 
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